17,261 trials
Tobacco Use Disorder
Primary: Feasibility of Progesterone as a Relapse Prevention Intervention for Postpartum Women With Pre-conception Smoking: Adherence to Treatment — 84.5; 76.0 doses of medication
Albinism · Vision Loss
Primary: Absolute Mean Change in Iris Pigmentation on an 8-point Iris Transillumination Scale at 12 Months as Compared to Baseline. Participants Left and Right Eyes Will be…
Influenza
Primary: Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain — 39; 45; 42; 46…
Oral Dystonia · Tardive Dystonia
Primary: Mean Global Dystonia Rating Scale Score as Measured by Blinded Rater — 3.80; 3.57; 3.71 units on a scale
Depressive Disorder, Major
Primary: Change From Randomization to the End of Treatment Phase (Week 6) in the Bech Melancholia Subscale (Bech) (Items 1, 2, 7, 8, 10 and 13) From the Hamilton Rating Scale for…
Cystic Fibrosis
Primary: Number of Participants With Adverse Events (AE) and Serious Adverse Events (SAE) — 46; 32; 32; 2 Participants
Huntington's Disease
Primary: Change From Baseline in the Total Motor Score (TMS) Assessment of the Unified Huntington Disease Rating Scale (UHDRS) After 26 Weeks of Treatment. — 0.4; -0.8; -1.4…
Hypophosphatasia
Primary: Long-term Tolerability of Subcutaneous (SC) Asfotase Alfa — 10 Participants
Hyperhidrosis
Primary: Mean Plasma Concentration After Repeat Dosing of Umeclidinium — 33.09; 29.86; 41.22; 42.72 picogram per millilitre (pg/ml)
Diffuse Large B Cell Lymphoma
Primary: Number of Participants With Adverse Events, Injection Site Reactions, and Concomitant Medications — 4; 1; 3 Participants
Bladder Cancer · Urothelial Carcinoma
Primary: Overall Survival — 6.4; 5.9 months
Depressive Disorder, Major
Primary: Change From Randomization (Week 0) Associated With GW856553 Versus Placebo at Week 6 in the Bech (6-item HAMD-17 [Hamilton Depression Rating Scale]) Score. — -6.5; -5.6…
Exudative Age-Related Macular Degeneration
Primary: Number of Subjects With Positive LUCENTIS® Retreatment Status at Day 84 — 25; 25 Participants
Actively Extending Plaque Psoriasis · Moderate to Severe Plaque Psoriasis
Primary: Mean Epidermal Thickness at End-of-Treatment (EOT) Compared to Pre-treatment — -8.8; -48.5; 17.3 Millimeters
Recurrent B-Cell Non-Hodgkin Lymphoma · Recurrent Chronic Lymphocytic Leukemia · Recurrent Indolent Adult Non-Hodgkin Lymphoma
Primary: Objective Response Rate — 97; 39 percentage of participants